drugset / Trial / NCT01545947
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each combination in order to evaluate their effects in future clinical trials for advanced non-small cell lung cancer.
Timeline
- Start
- 2012-05-01
- Primary completion
- 2014-12-11
- Completion
- 2014-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 200 mg | Oral |
| Subject | Azacitidine | Other / unclassified | 300 mg | Oral |
| Subject | Erlotinib | Small molecule | 100 mg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |
| Subject | ONATASERTIB | Small molecule | 15 mg | — |
| Subject | ONATASERTIB | Small molecule | 30 mg | — |